TY - JOUR
T1 - In silico approaches to RNA aptamer design
AU - Hamada, Michiaki
N1 - Funding Information:
M.H. is grateful to Aya Yokota, Ryoga Ishida, Yoshikazu Nakamura, Kazuteru Aoki, Masahiko Imashimizu, Masaki Takahashi, Eri Sakota, Tomoshi Kameda, Kiyoshi Asai, Shun Sakuraba and Tsukasa Fukunaga for valuable and insightful discussion. M.H. also thanks to the members in Hamada Laboratory at Waseda University and the members of the “AI Aptamer Workshop” held at the University of Tokyo. This study was supported by MEXT KAKENHI Grant numbers JP16H05879, JP16H01318, JP16H02484 and JP17K20032 to M.H.
Funding Information:
M.H. is grateful to Aya Yokota, Ryoga Ishida, Yoshikazu Nakamura, Kazuteru Aoki, Masahiko Imashimizu, Masaki Takahashi, Eri Sakota, Tomoshi Kameda, Kiyoshi Asai, Shun Sakuraba and Tsukasa Fukunaga for valuable and insightful discussion. M.H. also thanks to the members in Hamada Laboratory at Waseda University and the members of the “AI Aptamer Workshop” held at the University of Tokyo. This study was supported by MEXT KAKENHI Grant numbers JP16H05879 , JP16H01318 , JP16H02484 and JP17K20032 to M.H.
Publisher Copyright:
© 2017 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM)
PY - 2018/2
Y1 - 2018/2
N2 - RNA aptamers are ribonucleic acids that bind to specific target molecules. An RNA aptamer for a disease-related protein has great potential for development into a new drug. However, huge time and cost investments are required to develop an RNA aptamer into a pharmaceutical. Recently, SELEX combined with high-throughput sequencers (i.e., HT-SELEX) has been widely used to select candidate RNA aptamers that bind to a target protein with high affinity and specificity. After candidate selection, further optimizations such as shortening and modifying candidate sequences are performed. In these steps, in silico approaches are expected to reduce the time and cost associated with aptamer drug development. In this article, we review existing in silico approaches to RNA aptamer development, including a method for ranking the candidates of RNA aptamers from HT-SELEX data, clustering a huge number of aptamer sequences, and finding motifs amidst a set of significant RNA aptamers. It is expected that further studies in addition to these methods will be utilized for in silico RNA aptamer design, permitting a minimal number of experiments to be performed through the utilization of sophisticated computational methods.
AB - RNA aptamers are ribonucleic acids that bind to specific target molecules. An RNA aptamer for a disease-related protein has great potential for development into a new drug. However, huge time and cost investments are required to develop an RNA aptamer into a pharmaceutical. Recently, SELEX combined with high-throughput sequencers (i.e., HT-SELEX) has been widely used to select candidate RNA aptamers that bind to a target protein with high affinity and specificity. After candidate selection, further optimizations such as shortening and modifying candidate sequences are performed. In these steps, in silico approaches are expected to reduce the time and cost associated with aptamer drug development. In this article, we review existing in silico approaches to RNA aptamer development, including a method for ranking the candidates of RNA aptamers from HT-SELEX data, clustering a huge number of aptamer sequences, and finding motifs amidst a set of significant RNA aptamers. It is expected that further studies in addition to these methods will be utilized for in silico RNA aptamer design, permitting a minimal number of experiments to be performed through the utilization of sophisticated computational methods.
KW - Clustering
KW - HT-SELEX
KW - Motif finding
KW - RNA secondary structures
KW - SELEX
KW - Tertiary structure predictions
UR - http://www.scopus.com/inward/record.url?scp=85031787827&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031787827&partnerID=8YFLogxK
U2 - 10.1016/j.biochi.2017.10.005
DO - 10.1016/j.biochi.2017.10.005
M3 - Review article
C2 - 29032056
AN - SCOPUS:85031787827
SN - 0300-9084
VL - 145
SP - 8
EP - 14
JO - Biochimie
JF - Biochimie
ER -